Palboxen 125 MG (Palbociclib)

Basic Product Information of Palboxen (Palbociclib) 125mg

How Palboxen (Palbociclib) Works

Palboxen contains Palbociclib, a selective, reversible small-molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Cyclin D1 and CDK4/6 sit downstream of multiple signalling pathways that drive cellular proliferation, and their activity is required for a cell to progress from the G1 phase into the S phase of the cell division cycle. In hormone receptor-positive breast cancer, oestrogen signalling promotes cyclin D1 expression, driving continued tumour cell division.

By inhibiting CDK4/6, Palboxen blocks this G1-to-S phase transition, halting the proliferation of oestrogen receptor-positive breast cancer cells. In pre-clinical models, the combination of Palbociclib with endocrine therapy (an aromatase inhibitor or fulvestrant) produced greater anti-tumour activity than either approach alone, which is why Palboxen is always given as part of a combination regimen rather than as a standalone treatment.

Palboxen is taken as an oral capsule with food, using a distinctive 21 days on treatment, followed by 7 days off schedule, repeated in 28-day cycles.

Indications for Palboxen (Palbociclib)

Palboxen (Palbociclib) is indicated for the following conditions:

Benefits of Palboxen (Palbociclib) 125mg

How to Take Palboxen (Palbociclib)

Monitoring and Dosage Adjustments

Regular monitoring is essential throughout Palboxen treatment. Your oncologist will check complete blood counts before starting treatment, at the beginning of each cycle, and on Day 15 of the first two cycles, given the risk of neutropenia. Monitoring also includes assessment for signs of infection, and prompt evaluation of any new or worsening respiratory symptoms suggestive of interstitial lung disease or pneumonitis. Monitoring in line with the aromatase inhibitor or fulvestrant component of your regimen will also apply. Report any fever, chills, unusual bruising or bleeding, persistent fatigue, breathlessness, or cough to your oncology team immediately.

Drug Interactions and Important Information

Palbociclib is primarily metabolised by CYP3A and the sulfotransferase enzyme SULT2A1, and is itself a time-dependent inhibitor of CYP3A. Avoid concomitant use of Palboxen with strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, and clarithromycin) where possible; if unavoidable, a dose reduction to 75mg once daily is required. Avoid concomitant use with strong CYP3A4 inducers (such as rifampicin, carbamazepine, and phenytoin), as these reduce Palbociclib effectiveness. Avoid grapefruit and grapefruit juice during treatment.

Because Palboxen inhibits CYP3A, caution is advised with sensitive CYP3A substrate medications, which may need dose adjustment. Women of childbearing potential should use effective contraception during treatment and for at least 3 weeks after the final dose. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Palboxen.

Side Effects and Precautions

Who Should Use Palboxen (Palbociclib)?

Palboxen is suitable for adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer, whether being started on first-line endocrine-based therapy in combination with an aromatase inhibitor, or being treated with fulvestrant after progression on prior endocrine therapy. It is prescribed by medical oncologists experienced in managing HR-positive breast cancer. A thorough medical assessment including confirmed HR-positive/HER2-negative status, baseline blood counts, and a review of respiratory symptoms is required before initiating treatment.

Manufacturer: Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, and a recognised specialist in complex generic oncology formulations. Everest operates under strict WHO-GMP guidelines and maintains rigorous ISO certifications. To help ensure therapeutic equivalence to the innovator brand, Palboxen undergoes bioequivalence testing, checking the dissolution profile, peak plasma concentration, and overall drug exposure against the established safety and efficacy profile from the PALOMA clinical trial programme, with each batch examined in a certified laboratory before global distribution. Palboxen is one of Everest’s specialty oncology products, offering a bioequivalent alternative to Ibrance by Pfizer at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Palboxen (Palbociclib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Palboxen (Palbociclib) from Mediaid Pharmacy?

Palboxen represents a foundational advance in the treatment of HR-positive, HER2-negative advanced breast cancer, helping delay disease progression and the need for chemotherapy. As the generic equivalent of Ibrance by Pfizer, it delivers the same active ingredient, Palbociclib, with the same proven CDK4/6-inhibition mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under WHO-GMP and ISO-certified standards and distributed globally by Mediaid Pharmacy, Palboxen gives patients worldwide access to essential combination breast cancer therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Palbociclib option with worldwide delivery, Palboxen from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Palboxen (Palbociclib)